Aparna Raychaudhuri Selected Research

Lisdexamfetamine Dimesylate

12/2014	Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses.
10/2013	Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.
7/2013	Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aparna Raychaudhuri Research Topics

Disease

6	Dry Eye Syndromes (Dry Eye Syndrome) 07/2019 - 12/2015
2	Urinary Tract Infections (Urinary Tract Infection) 12/2022 - 01/2020
2	Pain (Aches) 07/2019 - 01/2017
2	Gonorrhea 12/2018 - 01/2018
2	Inflammation (Inflammations) 01/2017 - 12/2015
2	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 10/2013 - 07/2013
2	Multiple Sclerosis 09/2008 - 09/2006
1	Plague (Bubonic Plague) 01/2022
1	Bacterial Infections (Bacterial Infection) 01/2022
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2020
1	Dysgeusia (Parageusia) 07/2019
1	Pruritus (Itching) 01/2017
1	Photophobia (Light Sensitivity) 01/2017
1	Foreign Bodies (Foreign Body) 01/2017
1	Schizophrenia (Dementia Praecox) 12/2014
1	Infections 09/2008
1	Pathologic Complete Response 09/2008
1	Relapsing-Remitting Multiple Sclerosis 09/2008
1	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 09/2007
1	Breast Neoplasms (Breast Cancer) 09/2006

Drug/Important Bio-Agent (IBA)

6	lifitegrastIBA 07/2019 - 12/2015
5	gepotidacinIBA 12/2022 - 01/2018
3	Lisdexamfetamine Dimesylate FDA Link 12/2014 - 07/2013
2	Nitrofurantoin (Macrodantin)FDA LinkGeneric 12/2022 - 01/2020
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 01/2020
2	InterleukinsIBA 09/2008 - 09/2006
2	Interleukin-12 (IL 12)IBA 09/2008 - 09/2006
2	Monoclonal AntibodiesIBA 09/2008 - 09/2006
1	DNA Topoisomerase IV (Topoisomerase IV)IBA 01/2022
1	Bacterial DNAIBA 01/2022
1	Topoisomerase InhibitorsIBA 01/2018
1	Lymphocyte Function-Associated Antigen-1 (LFA-1)IBA 01/2017
1	IntegrinsIBA 12/2015
1	Dextroamphetamine (Dexedrine)FDA LinkGeneric 12/2014
1	ProdrugsIBA 12/2014
1	Antipsychotic Agents (Antipsychotics)IBA 12/2014
1	GadoliniumIBA 09/2008
1	Ustekinumab (CNTO 1275)FDA Link 09/2008
1	Infliximab (Remicade)FDA Link 09/2007
1	Methotrexate (Mexate)FDA LinkGeneric 09/2007

Therapy/Procedure

1	Renal Dialysis (Hemodialysis) 01/2020
1	Therapeutics 12/2018
1	Drug Therapy (Chemotherapy) 12/2014
1	Subcutaneous Injections 09/2008